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There is a strong, positive, independent, continuous, graded
relation between hypercholesterolemia and the risk for
coronary heart disease (CAD). In clinical trials, it has been
shown that 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors or statins inhibit HMG-
CoA reductase competitively, reduce LDL levels more than
other cholesterol-lowering drugs and lower triglyceride
levels in hypertriglyceridemic patients (1,2). Prospective,
controlled trials have demonstrated beyond doubt that
statins reduce the relative risk of major coronary events by
;30%. This has been shown in trials involving patients with
and without CAD and with and without hypercholesterol-
emia (3–7). Accordingly, lipid lowering by means of statin
therapy is now widely applied in clinical practice.
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Coronary artery disease is the underlying structural heart
disease in .80% of victims of life-threatening ventricular
tachyarrhythmias such as syncopal ventricular tachycardia
(VT) or ventricular fibrillation (VF) (8). Therefore, one
could speculate that treatment of hypercholesterolemia
would result not only in a reduction of major ischemic
events, but ultimately also in a reduction of arrhythmic
episodes in high risk patients with coronary disease. Unfor-
tunately, at present, this hypothesis has not been proven
beyond doubt in the large primary and secondary prevention
trials (3–7). However, two secondary prevention trials have
provided some evidence in support of this hypothesis. In the
Scandinavian Simvastatin Survival Study (4S) (3), the pri-
mary study end point was total mortality. However, data on
instantaneous death and death within 1 h—both most likely
due to VT or VF—are provided; in the placebo group, this
accounted for 63 of 189 coronary deaths, as compared with
37 of 111 coronary deaths in the simvastatin group. This
reduction in presumably arrhythmic death was comparable
to the reduction of death due to definite acute myocardial
infarction (63 vs. 30 deaths). The level of significance,
however, for instantaneous death alone was not provided
(3). The second trial providing at least some evidence for
this hypothesis is the Long-term Intervention with Prava-
statin in Ischemic Disease (LIPID) study (5). This trial used
death from coronary heart disease as its primary end point
(5). Among the 4,502 patients in the placebo group, 211
deaths were classified by the Events Committee as sudden
death, as compared with 182 such deaths in the 4,512
pravastatin-treated patients. Again, no separate statistical
analysis of this mode of death was reported, but this
observation supports a beneficial effect of statins on the
incidence of arrhythmia-related death in patients with
coronary events.
Mechanisms of statin-associated benefits in CAD. An
important observation made in secondary and primary
prevention trials was that the statin-associated beneficial
effects occurred relatively early. Accordingly, retardation of
plaque development due to cholesterol lowering could not
be the sole reason for the beneficial treatment effects. It is
now well appreciated that statins have beneficial effects
above and beyond their hypercholesterolemia-lowering
capability (1,2). For instance, statins improve endothelial
function (9–11) by lowering cholesterol levels and thereby
reducing oxidative stress within the vascular wall (12,13).
However, statins also have direct effects on vascular
biology—independent of their lipid-lowering properties—
such as activation of the atheroprotective enzyme nitric
oxidase synthase (14), and probably they influence the
mevalonate pathway (15). Thus, in addition to reducing
oxidative stress, statins counteract the inflammatory process
in atherosclerotic plaques and interfere with vascular wall
proliferation processes (1,2,16). Accordingly, besides reduc-
ing the lipid pool within the plaque, cholesterol lowering
with statins may help to stabilize the atherosclerotic plaque
and prevent cardiovascular events. Hypercholesterolemia is
also associated with hypercoagulability and enhanced plate-
let reactivity at sites of acute vascular damage (2). There is
accumulating evidence that statins may favorably affect
thrombus formation, erythrocyte deformability and levels of
plasminogen activator inhibitor-1 and fibrinogen (1,2). It
has been suggested that the last three effects associated with
statin therapy improve hemorheologic characteristics early
in the course of therapy (2). In accordance with this
hypothesis, both lovastatin and pravastatin significantly
reduce the frequency and intensity of ischemic episodes
detected by Holter monitoring after as little as 16 weeks of
therapy (17,18).
Lipid-lowering therapy and ventricular tachyarrhyth-
mias. In this issue of the Journal, De Sutter et al. (19)
report their results of 78 patients with CAD and a history of
life-threatening arrhythmias. All of these patients were
fitted with an implantable cardioverter defibrillator (ICD), a
therapy that has been shown to be superior to antiarrhyth-
mic drug therapy for prevention of recurrent sudden death
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(20–22). Twenty-seven of these patients were receiving
lipid-lowering therapy, and 51 were not. After an average
follow-up period of 490 days, device activation occurred
significantly more often in patients without versus with
lipid-lowering therapy. In fact, absence of lipid-lowering
therapy was independently associated with recurrent VT or
VF on multivariate analysis, even after correcting for other
treatment imbalances, particularly the use of antiadrenergic
therapy. Although the results of this study appear to support
the aforementioned benefits of lipid-lowering treatments,
some words of caution are appropriate.
The major limitations of this study are its retrospective,
observational design and the relatively small patient group,
as stated by the authors. Accordingly, a finding by chance is
considerable. Moreover, there are some imbalances regard-
ing pharmacologic therapy of both patient groups, aside
from the use of lipid-lowering agents. Beta-blockers were
administered in 65% of patients without subsequent ICD
interventions, as compared with only 34% of those with
device therapy during follow-up (p 5 0.012). Beta-blockers
are well known to suppress life-threatening arrhythmias
(23). Accordingly, this is of concern despite the fact that
subgroup analysis of individuals on beta-blockers (yielding
very small sample sizes) indicates that lipid-lowering drugs
continued to be associated with fewer ICD activations.
Only one of the three secondary ICD prevention trials
has reported data on the use of lipid-lowering therapy (24).
In the Antiarrhythmics Versus Implantable Defibrillators
trial (AVID), 132 of 1,016 patients received such treatment.
In contrast to the results of the present study (19), there was
no difference regarding the primary study end point of total
mortality between patients with and without lipid-lowering
drugs (24). This finding was consistent in patients treated
with the ICD or antiarrhythmic drug therapy.
Myocardial ischemia and sudden death due to VT or VF.
It is tempting to speculate on the mechanism(s) by which
lipid-lowering therapy could influence the likelihood of
recurrent VT or VF in high risk patients. At least 80% of
patients who experience sudden death have coronary disease
as the underlying anatomic substrate (8). Autopsy studies
have found recent occlusive coronary thrombus in 15% to
64% of victims of sudden cardiac death (8,25). Accordingly,
sudden cardiac death may be divided into instantaneous
death that appears to be caused by primary arrhythmic
events, and death occurring several hours after the onset of
symptoms that are thought to be related to arrhythmias that
arose in the setting of acute myocardial ischemia or infarc-
tion (26). The hearts of victims of instantaneous death had
fewer coronary lesions but more extensive scarring and old
coronary artery occlusions as compared with the hearts of
those who did not die instantaneously (26). In patients
without a history of heart disease, acute myocardial ischemia
may be more often responsible for sudden death. Alterna-
tively, in patients with impaired left ventricular function and
scars from a previous infarction, acute ischemia is usually
less important. Of note, the patients enrolled in the study of
De Sutter et al. (19) had markedly reduced left ventricular
ejection fractions, indicating that they may belong to the
latter group of sudden death victims. This is in accordance
with other recent findings, for instance, those reported by
the AVID investigators (24). In the AVID study, the causes
of death in 1,016 patients enrolled in this secondary
prevention trial were analyzed. It was found that only 4 of
79 arrhythmic deaths were associated with markers of
ischemia (24). The authors therefore concluded that the
majority of events were unrelated to measurable ischemia.
This notion is supported by numerous previous small trials
(27,28). Accordingly, in the context of the potential benefits
of lipid-lowering therapy for reduction of arrhythmic
events, it is reasonable to assume that the potential antiar-
rhythmic effects of statins should be linked to their ability to
reduce the ischemic burden of the myocardium, but there is
much less reason why these agents should act on the
arrhythmic substrate.
Clinical implications. There is sound evidence that lipid-
lowering therapy, particularly statins, reduce cardiovascular
mortality and morbidity in patients with CAD. That statins
exert part of this beneficial effect by reducing the likelihood
of arrhythmia-related sudden cardiac death is a tempting
hypothesis that has not been proven yet. The study of De
Sutter et al. (19) should trigger further careful examination
of this hypothesis. Their conclusion that prospective, well-
designed, randomized trials are needed to confirm this
hypothesis is valid. Such trials would also be potentially
helpful in defining the role of acute myocardial ischemia as
a trigger for sudden cardiac death in more detail. Apart from
this, survivors of VT or VF need to be carefully and
repeatedly screened for hypercholesterolemia to promptly
institute statin therapy where appropriate.
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